US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PMGC Holdings

2.34

+0.05202.27%

Volume:77.52K

Turnover:180.48K

Market Cap:2.07M

PE:-0.03

High:2.40

Open:2.29

Low:2.25

Close:2.29

Loading ...

Overview Company News Filings

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial

BRIEF-PMGC Holdings Enters Sales Agreement With Univest Securities

BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment

Northstrive Biosciences Announces Positive FDA Response Supporting a Submission of Ind for a Phase 2 Clinical Trial for El-22 in Combination With Glp-1 Receptor Agonist for Obesity Treatment

THOMSON REUTERS

Pmgc Holdings Inc - Northstrive to File Ind Application in 2025

THOMSON REUTERS

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

Pmgc Holdings Inc - Enters Sales Agreement With Univest Securities - SEC Filing

THOMSON REUTERS

Pmgc Holdings Inc - to Issue and Sell up to $100 Million in Common Stock - SEC Filing

THOMSON REUTERS

PMGC Holdings Announces Acquisition of IT Packaging Firm

PMGC Signs Letter of Intent to Purchase Custom IT Packaging Firm; Shares Fall

MT Newswires Live

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company

Northstrive Biosciences Signs Partnership With Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

THOMSON REUTERS

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K

Northstrive Biosciences Inc. Signs Amended Licensing Agreement With Existing Licensor, Aims to Capture Animal Health Market

THOMSON REUTERS

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

Univest Securities, Llc Announces Closing of $1.48 Million Registered Direct Offering for Its Client Pmgc Holdings Inc. (Nasdaq: Elab)

THOMSON REUTERS

PMGC Holdings Inc trading resumes

BRIEF-PMGC Holdings Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ELAB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELAB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELAB\",,,,,undefined,":{"symbol":"ELAB","market":"US","secType":"STK","nameCN":"PMGC Holdings","latestPrice":2.342,"timestamp":1746128467996,"preClose":2.29,"halted":0,"volume":77523,"delay":0,"floatShares":768300,"shares":884400,"eps":-78.48178,"marketStatus":"Trading","change":0.052,"latestTime":"05-01 15:42:33 EDT","open":2.29,"high":2.4,"low":2.2501,"amount":180483.234375,"amplitude":0.065459,"askPrice":2.36,"askSize":3000,"bidPrice":2.32,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-78.48178,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":2,"adr":0,"listingDate":1700542800000,"exchange":"NASDAQ","adjPreClose":2.29,"preHourTrading":{"tag":"盘前","latestPrice":2.34,"preClose":2.29,"latestTime":"09:22 EDT","volume":4030,"amount":9467.929263,"timestamp":1746105763028},"postHourTrading":{"tag":"盘后","latestPrice":2.28,"preClose":2.29,"latestTime":"19:50 EDT","volume":2899,"amount":6623.4387,"timestamp":1746057054530},"volumeRatio":0.059649},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELAB\",,,,,undefined,":{"symbol":"ELAB","floatShares":768300,"roa":"-30.40%","roe":"-76.61%","lyrEps":-78.481779,"volumeRatio":0.059649,"shares":884400,"dividePrice":0,"high":2.4,"amplitude":0.065459,"preClose":2.29,"low":2.2501,"week52Low":2.14,"pbRate":"0.31","psRate":"0.85","week52High":1064,"institutionHeld":0,"latestPrice":2.342,"committee":-0.993355,"eps":-78.48178,"divideRate":0,"volume":77523,"delay":0,"ttmEps":-78.48178,"open":2.29,"prevYearClose":16.03,"prevWeekClose":2.26,"prevMonthClose":2.29,"prevQuarterClose":4.63,"fiveDayClose":2.22,"twentyDayClose":4.55,"sixtyDayClose":12.18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELAB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531173250","title":"Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2531173250","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531173250?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"NEWPORT BEACH, Calif., April 29, 2025  -- Northstrive Biosciences Inc. , a subsidiary of PMGC Holdings Inc.  , today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists.The Company filed the following four patents today:. EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals .EL-32 in Obesity as Monotherapy and Combination with GLP-1: Updated patent filings for Pharmaceutical Composition for Treatment of Muscle Loss Due to Obesity Treatments , and Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments utilizing GLP-1 receptor agonists .“We believe that EL-22 and EL-32 have the potential to treat obesity in combination with GLP-1 receptor agonists, while also serving as the foundation to a potential range of ani","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northstrive-biosciences-strengthens-ip-portfolio-120000070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELAB","LU1169590202.USD","LU2463526074.USD","LU2404859667.USD","IE00B3T34201.USD","BK4504","LU1169589451.USD","BK4588","LU0690374615.EUR","LU1487256676.USD","LU2552382058.USD","VAQC","BK4183","LU2552382215.SGD","BK4136","EL","BK4585","BK4533","LU2404859741.USD","LU1481600234.SGD","IP","LU2552382132.HKD","BK4548","BK4558","LU0690374961.EUR","BK4561","LU1481599808.USD"],"gpt_icon":0},{"id":"2530440591","title":"Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530440591","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530440591?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"NEWPORT BEACH, Calif., April 28, 2025  -- Northstrive Biosciences Inc. , a subsidiary of PMGC Holdings Inc.  , is proud to announce that Co-Founder Deniel Mero was recently featured in an exclusive interview hosted by Bear Bull Traders, a leading global online stock trading community for professional and aspiring traders.During the interview, Mr. Mero discussed Northstrive’s recent milestone: receiving preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists. EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.Bear Bull Traders is an international trading education community founded in 2015 by Andrew Aziz. With over 100,000 members globally, Bear Bull Traders offers comprehensive education, expert mentorship, and community supp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northstrive-biosciences-co-founder-featured-120000019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EL","BK4585","BK4533","BK4504","BK4183","LU0690374961.EUR","LU0690374615.EUR","LU2552382132.HKD","BK4548","LU2552382215.SGD","LU2552382058.USD","BK4558","LU2404859741.USD","BK4588","ELAB","LU2404859667.USD"],"gpt_icon":0},{"id":"2529592987","title":"BRIEF-PMGC Holdings Enters Sales Agreement With Univest Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2529592987","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529592987?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:57","pubTimestamp":1745499476,"startTime":"0","endTime":"0","summary":"BRIEF-PMGC Holdings Enters Sales Agreement With Univest SecuritiesApril 24  - PMGC Holdings Inc ELAB.O:PMGC HOLDINGS INC - ENTERS SALES AGREEMENT WITH UNIVEST SECURITIES - SEC FILINGPMGC HOLDINGS INC - TO ISSUE AND SELL UP TO $100 MILLION IN COMMON STOCK - SEC FILINGFurther company coverage: ELAB.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R225T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAB"],"gpt_icon":0},{"id":"2529166989","title":"BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529166989","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529166989?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:18","pubTimestamp":1745497096,"startTime":"0","endTime":"0","summary":"BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity TreatmentApri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA5MCKTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2529986363","title":"Northstrive Biosciences Announces Positive FDA Response Supporting a Submission of Ind for a Phase 2 Clinical Trial for El-22 in Combination With Glp-1 Receptor Agonist for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986363?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496057,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA5MCKTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2529868269","title":"Pmgc Holdings Inc - Northstrive to File Ind Application in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529868269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529868269?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496057,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA5MCKTP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2529354269","title":"Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529354269","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529354269?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists.Northstrive believes the FDA responses encourage a path forward for filing an IND application to conduct a Phase 2 clinical trial in overweight or obese patients.EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.NEWPORT BEACH, Calif., April 24, 2025  -- Northstrive Biosciences Inc. , a subsidiary of PMGC Holdings Inc.  , announced that it has received preliminary responses and commentary from the U.S. Food and Drug Administration  regarding its scheduled Type B pre-Investigational New Drug  meeting. Northstrive initially requested this meeting with the FDA to discuss nonclinical studies and Northstrive Biosciences’ clinical development p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northstrive-biosciences-announces-positive-fda-120000281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELAB","GLP","LU2552382058.USD","BK4144","LU2404859667.USD","BK4183","BK4585","LU0690374615.EUR","BK4548","LU2552382132.HKD","LU2404859741.USD","LU2552382215.SGD","EL","BK4558","BK4504","BK4590","LU0690374961.EUR","BK4533","BK4588"],"gpt_icon":0},{"id":"2529605494","title":"Pmgc Holdings Inc - Enters Sales Agreement With Univest Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529605494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529605494?lang=en_us&edition=fundamental","pubTime":"2025-04-24 18:19","pubTimestamp":1745489962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R225T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2529492605","title":"Pmgc Holdings Inc - to Issue and Sell up to $100 Million in Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529492605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529492605?lang=en_us&edition=fundamental","pubTime":"2025-04-24 18:19","pubTimestamp":1745489962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R225T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2528926427","title":"PMGC Holdings Announces Acquisition of IT Packaging Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2528926427","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528926427?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:35","pubTimestamp":1744886104,"startTime":"0","endTime":"0","summary":"The latest update is out from ELEVAI Labs Inc. ( ($ELAB) ). On April 16, 2025, PMGC Holdings Inc. announced the signing of a non-binding Letter of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pmgc-holdings-announces-acquisition-of-it-packaging-firm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pmgc-holdings-announces-acquisition-of-it-packaging-firm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2528221772","title":"PMGC Signs Letter of Intent to Purchase Custom IT Packaging Firm; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2528221772","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528221772?lang=en_us&edition=fundamental","pubTime":"2025-04-17 00:19","pubTimestamp":1744820368,"startTime":"0","endTime":"0","summary":"PMGC Holdings  said Wednesday it has signed a non-binding letter of intent to buy an unnamed US-based information technology custom packaging firm.The target company has \"close to 15 years of uninterrupted operations\" and consistently delivered positive earnings before interest, taxes, depreciation, and amortisation performance year over year, PMGC said.PMGC said it expects to sign a definitive agreement and close the deal before the end of Q2, subject to customary conditions.The deal marks the launch of PMGC's previously announced acquisition strategy, the company said, adding this is the \"first of several accretive acquisitions shareholders can expect in the months ahead.\"Price: 2.51, Change: -0.40, Percent Change: -13.78","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2527290211","title":"PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2527290211","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527290211?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:00","pubTimestamp":1744804800,"startTime":"0","endTime":"0","summary":"Acquisition Target Currently Serves over 300 Commercial Clients, which Includes Data Centers, Technology Manufacturers, and IT Service Providers with Close to 15 Years of Operational History, 90% U.S.-Based Revenue, and Recurring Business. NEWPORT BEACH, Calif., April 16, 2025  -- PMGC Holdings Inc.  , a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent  to acquire a U.S.-based, cash-flow positive information technology  custom packaging company.Founded in 2011 and headquartered in Southern California, the Target is a well-established provider of custom packaging solutions for IT products, serving over 300 commercial clients—including data centers, technology manufacturers, and IT service providers. With close to 15 years of uninterrupted operations, the company has built a loyal, predominantly U.S.-based customer base (90%) and consistently delivered positive EBITDA performance year over year.The closing of this acquisition is sub","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pmgc-holdings-inc-signs-letter-120000669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELAB"],"gpt_icon":0},{"id":"2526563353","title":"Northstrive Biosciences Signs Partnership With Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563353?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:01","pubTimestamp":1744286500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2526631595","title":"Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2526631595","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526631595?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:00","pubTimestamp":1744286400,"startTime":"0","endTime":"0","summary":"Northstrive Biosciences and Yuva Biosciences’ collaboration will leverage MitoNova, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/10/3059185/0/en/Northstrive-Biosciences-Signs-Partnership-with-Yuva-Biosciences-to-Develop-AI-Powered-Therapies-for-Obesity-and-Cardiometabolic-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2522707575","title":"PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707575","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707575?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"NEWPORT BEACH, Calif., March 28, 2025  -- PMGC Holdings Inc.   today announced that it has filed its Annual Report on Form 10-K  for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission .The Annual Report is available on the SEC’s website at www.sec.gov under the company’s filings, as well as on the Company’s investor relations website.PMGC remains dedicated to innovative solutions and delivering long-term value for its shareholders. As part of its strategic growth initiatives, the Company has engaged in an active search for acquisition opportunities involving operating businesses and assets with the potential to drive meaningful revenue growth and enhance shareholder value.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pmgc-holdings-inc-announces-filing-120000755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2522071374","title":"Northstrive Biosciences Inc. Signs Amended Licensing Agreement With Existing Licensor, Aims to Capture Animal Health Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2522071374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522071374?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA1VLFML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2522177372","title":"NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2522177372","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522177372?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"The U.S. animal health market was valued at USD 12.65 billion in 2024 and is expected to grow at a CAGR of 7.97% from 2025 to 2030. This growth is believed to be a consequence of rising innovations surrounding companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations and production in developing countries, and increasing meat or milk consumption rates, coupled with rising concerns about food-borne diseases.Northstrive Biosciences Inc.’s amendment to its existing licensing agreement allows the company to develop and commercialize a comprehensive range of animal health products, including pharmaceuticals and feed additives. The company believes these products are essential for improving animal health, productivity, and overall food security.The Company believes this expanded scope of its license rights with MOA will position NorthStrive Biosciences to potentially capture new revenue streams from high-growth markets and lower its barrier to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northstrive-biosciences-inc-signs-amended-120000713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2522088229","title":"Univest Securities, Llc Announces Closing of $1.48 Million Registered Direct Offering for Its Client Pmgc Holdings Inc. (Nasdaq: Elab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522088229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522088229?lang=en_us&edition=fundamental","pubTime":"2025-03-25 05:00","pubTimestamp":1742850000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA1RHBRW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2521554312","title":"PMGC Holdings Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2521554312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521554312?lang=en_us&edition=fundamental","pubTime":"2025-03-22 02:55","pubTimestamp":1742583307,"startTime":"0","endTime":"0","summary":"14:51 EDT PMGC (ELAB) Holdings Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pmgc-holdings-inc-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pmgc-holdings-inc-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2521548255","title":"BRIEF-PMGC Holdings Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2521548255","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521548255?lang=en_us&edition=fundamental","pubTime":"2025-03-22 02:50","pubTimestamp":1742583056,"startTime":"0","endTime":"0","summary":"BRIEF-PMGC Holdings Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq RulesMarch 21 (Reuters) - PMGC Holdings Inc ELAB.O:PMGC HOLDINGS INC. ANNOUNCES $1.48 MILLION R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA3TCZM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAB","BK4183"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELAB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-10","symbol":"ELAB","defaultRemindTime":1741613400000,"type":"split","dateTimestamp":1741579200000,"forFactor":7,"toFactor":1,"ratio":7},{"market":"US","date":"2024-11-27","symbol":"ELAB","defaultRemindTime":1732717800000,"type":"split","dateTimestamp":1732683600000,"forFactor":200,"toFactor":1,"ratio":200}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELAB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELAB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELAB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELAB","date":"2025-04-30","current":-0.264921,"percent":0.955621,"low":-19.933298,"twenty":-3.236529,"median":-1.423263,"eighty":-0.676786,"high":-0.185003,"avg":-2.614867,"sd":3.180725,"marketCap":1654628},"quantilePoints":[{"date":"2023-11-24","current":-18.255744,"twenty":-17.959705,"median":-17.515646,"eighty":-17.071587,"marketCap":64119575},{"date":"2023-12-01","current":-13.864497,"twenty":-19.360956,"median":-18.255744,"eighty":-16.918634,"marketCap":48696218},{"date":"2023-12-08","current":-10.509387,"twenty":-18.255744,"median":-15.443372,"eighty":-11.703412,"marketCap":36912079},{"date":"2023-12-15","current":-8.308155,"twenty":-18.10279,"median":-11.940243,"eighty":-9.335099,"marketCap":31539899},{"date":"2023-12-22","current":-8.354717,"twenty":-17.34789,"median":-10.682077,"eighty":-8.450306,"marketCap":31716661},{"date":"2023-12-29","current":-8.216856,"twenty":-16.918634,"median":-10.164008,"eighty":-8.299025,"marketCap":31193307},{"date":"2024-01-05","current":-7.303872,"twenty":-15.709807,"median":-9.153506,"eighty":-8.280766,"marketCap":27727384},{"date":"2024-01-12","current":-8.125558,"twenty":-14.012516,"median":-8.832664,"eighty":-8.070779,"marketCap":30846714},{"date":"2024-01-19","current":-4.884465,"twenty":-13.479646,"median":-8.376629,"eighty":-7.906442,"marketCap":18542688},{"date":"2024-01-26","current":-3.42369,"twenty":-11.881035,"median":-8.330979,"eighty":-7.359564,"marketCap":12997211},{"date":"2024-02-02","current":-3.834533,"twenty":-11.486317,"median":-8.216856,"eighty":-4.738387,"marketCap":14556876},{"date":"2024-02-09","current":-2.921549,"twenty":-10.785691,"median":-8.079909,"eighty":-3.801666,"marketCap":11090953},{"date":"2024-02-16","current":-3.323718,"twenty":-10.440311,"median":-7.942961,"eighty":-3.414564,"marketCap":12617692},{"date":"2024-02-23","current":-3.218269,"twenty":-10.164008,"median":-7.897312,"eighty":-3.378041,"marketCap":12217378},{"date":"2024-03-01","current":-3.181749,"twenty":-9.179141,"median":-7.443102,"eighty":-3.218269,"marketCap":12078741},{"date":"2024-03-08","current":-3.378041,"twenty":-9.127872,"median":-4.975763,"eighty":-3.263918,"marketCap":12823915},{"date":"2024-03-15","current":-3.555616,"twenty":-8.855945,"median":-4.679044,"eighty":-3.323718,"marketCap":13498037},{"date":"2024-03-22","current":-3.491707,"twenty":-8.832664,"median":-3.834533,"eighty":-3.332848,"marketCap":13255422},{"date":"2024-03-28","current":-3.149795,"twenty":-8.668692,"median":-3.638241,"eighty":-3.254788,"marketCap":11957434},{"date":"2024-04-05","current":-2.739531,"twenty":-8.426843,"median":-3.539867,"eighty":-3.191975,"marketCap":11784138},{"date":"2024-04-12","current":-2.578785,"twenty":-8.359099,"median":-3.514988,"eighty":-3.15016,"marketCap":11092686},{"date":"2024-04-19","current":-2.356802,"twenty":-8.353987,"median":-3.494218,"eighty":-3.138017,"marketCap":10137824},{"date":"2024-04-26","current":-2.715358,"twenty":-8.317285,"median":-3.457927,"eighty":-2.966103,"marketCap":11680160},{"date":"2024-05-03","current":-2.840249,"twenty":-8.271636,"median":-3.430537,"eighty":-2.908834,"marketCap":12217378},{"date":"2024-05-10","current":-2.751214,"twenty":-8.225986,"median":-3.400866,"eighty":-2.810275,"marketCap":11834394},{"date":"2024-05-17","current":-2.439543,"twenty":-8.198597,"median":-3.378041,"eighty":-2.734696,"marketCap":11265982},{"date":"2024-05-24","current":-2.476318,"twenty":-8.139253,"median":-3.346086,"eighty":-2.649774,"marketCap":11435812},{"date":"2024-05-31","current":-2.456058,"twenty":-8.070779,"median":-3.333761,"eighty":-2.615446,"marketCap":11342250},{"date":"2024-06-07","current":-2.620224,"twenty":-8.03426,"median":-3.293818,"eighty":-2.590871,"marketCap":12100380},{"date":"2024-06-14","current":-2.536364,"twenty":-7.99774,"median":-3.211422,"eighty":-2.574044,"marketCap":11713111},{"date":"2024-06-21","current":-2.409546,"twenty":-7.933831,"median":-3.194759,"eighty":-2.543297,"marketCap":11127455},{"date":"2024-06-28","current":-2.408319,"twenty":-7.915572,"median":-3.18814,"eighty":-2.539819,"marketCap":11121788},{"date":"2024-07-05","current":-2.340001,"twenty":-7.897312,"median":-3.163489,"eighty":-2.517446,"marketCap":10806289},{"date":"2024-07-12","current":-2.148137,"twenty":-7.860792,"median":-3.149795,"eighty":-2.484198,"marketCap":9920249},{"date":"2024-07-15","current":-2.063455,"twenty":-7.842533,"median":-3.149795,"eighty":-2.476543,"marketCap":9529182},{"date":"2024-08-02","current":-1.8,"twenty":-7.824273,"median":-3.149795,"eighty":-2.472639,"marketCap":8312530},{"date":"2024-08-09","current":-1.490993,"twenty":-7.627068,"median":-3.134046,"eighty":-2.438304,"marketCap":6885510},{"date":"2024-08-16","current":-1.275527,"twenty":-7.359564,"median":-3.024259,"eighty":-2.416511,"marketCap":6059653},{"date":"2024-08-23","current":-0.996722,"twenty":-6.536966,"median":-2.921549,"eighty":-2.408074,"marketCap":4735130},{"date":"2024-08-30","current":-1.174958,"twenty":-5.249658,"median":-2.921549,"eighty":-2.362653,"marketCap":5581877},{"date":"2024-09-06","current":-1.375091,"twenty":-4.920984,"median":-2.840249,"eighty":-2.345852,"marketCap":6532648},{"date":"2024-09-13","current":-1.357574,"twenty":-4.774907,"median":-2.7913,"eighty":-2.312486,"marketCap":6449430},{"date":"2024-09-20","current":-1.33918,"twenty":-4.674479,"median":-2.751214,"eighty":-2.26391,"marketCap":6362050},{"date":"2024-09-27","current":-0.556488,"twenty":-4.272766,"median":-2.706294,"eighty":-1.721618,"marketCap":2643710},{"date":"2024-10-04","current":-0.825353,"twenty":-3.907572,"median":-2.663183,"eighty":-1.516044,"marketCap":3921009},{"date":"2024-10-11","current":-0.609011,"twenty":-3.809883,"median":-2.623475,"eighty":-1.448755,"marketCap":2893229},{"date":"2024-10-18","current":-0.543983,"twenty":-3.700324,"median":-2.618669,"eighty":-1.401366,"marketCap":2584301},{"date":"2024-10-25","current":-0.958273,"twenty":-3.624547,"median":-2.598328,"eighty":-1.356698,"marketCap":4552470},{"date":"2024-10-31","current":-0.965548,"twenty":-3.591497,"median":-2.58341,"eighty":-1.330061,"marketCap":4587034},{"date":"2024-11-08","current":-0.186042,"twenty":-3.543017,"median":-2.570883,"eighty":-1.290658,"marketCap":883831},{"date":"2024-11-15","current":-0.272307,"twenty":-3.520466,"median":-2.545057,"eighty":-1.259215,"marketCap":1293652},{"date":"2024-11-22","current":-1.912035,"twenty":-3.514988,"median":-2.532982,"eighty":-1.195453,"marketCap":10456757},{"date":"2024-11-29","current":-0.970216,"twenty":-3.514075,"median":-2.507089,"eighty":-1.176604,"marketCap":5306027},{"date":"2024-12-06","current":-0.979681,"twenty":-3.507684,"median":-2.495456,"eighty":-1.057426,"marketCap":5357793},{"date":"2024-12-13","current":-1.055406,"twenty":-3.495725,"median":-2.476318,"eighty":-1.052022,"marketCap":5771922},{"date":"2024-12-20","current":-1.320411,"twenty":-3.487233,"median":-2.449166,"eighty":-1.053364,"marketCap":7221213},{"date":"2024-12-27","current":-1.354124,"twenty":-3.469339,"median":-2.436446,"eighty":-1.055406,"marketCap":7405585},{"date":"2025-01-03","current":-1.393455,"twenty":-3.460209,"median":-2.417636,"eighty":-1.071656,"marketCap":7620685},{"date":"2025-01-10","current":-1.18556,"twenty":-3.45108,"median":-2.415433,"eighty":-1.087177,"marketCap":6483728},{"date":"2025-01-17","current":-1.208035,"twenty":-3.441037,"median":-2.409546,"eighty":-1.102066,"marketCap":6606642},{"date":"2025-01-24","current":-1.112516,"twenty":-3.431907,"median":-2.407092,"eighty":-1.109145,"marketCap":6084256},{"date":"2025-01-31","current":-0.955191,"twenty":-3.419127,"median":-2.368422,"eighty":-1.085209,"marketCap":5223856},{"date":"2025-02-07","current":-1.039472,"twenty":-3.407716,"median":-2.352273,"eighty":-1.05223,"marketCap":5684785},{"date":"2025-02-14","current":-0.955191,"twenty":-3.391736,"median":-2.340001,"eighty":-1.033105,"marketCap":5223856},{"date":"2025-02-21","current":-0.915859,"twenty":-3.378041,"median":-2.326586,"eighty":-0.998824,"marketCap":5008756},{"date":"2025-02-28","current":-0.668633,"twenty":-3.378041,"median":-2.304429,"eighty":-0.984457,"marketCap":3656699},{"date":"2025-03-07","current":-0.406293,"twenty":-3.378041,"median":-2.256137,"eighty":-0.973171,"marketCap":2221982},{"date":"2025-03-14","current":-0.413918,"twenty":-3.37165,"median":-2.063455,"eighty":-0.968145,"marketCap":2263682},{"date":"2025-03-21","current":-0.675785,"twenty":-3.34426,"median":-1.851285,"eighty":-0.96081,"marketCap":3695808},{"date":"2025-03-28","current":-0.778466,"twenty":-3.336318,"median":-1.604046,"eighty":-0.955191,"marketCap":4257365},{"date":"2025-04-04","current":-0.500407,"twenty":-3.333578,"median":-1.540289,"eighty":-0.934537,"marketCap":3125408},{"date":"2025-04-11","current":-0.363417,"twenty":-3.331022,"median":-1.490993,"eighty":-0.836712,"marketCap":2269810},{"date":"2025-04-17","current":-0.292093,"twenty":-3.323718,"median":-1.4582,"eighty":-0.778466,"marketCap":1824333},{"date":"2025-04-25","current":-0.251335,"twenty":-3.263918,"median":-1.443055,"eighty":-0.679871,"marketCap":1569775},{"date":"2025-04-30","current":-0.264921,"twenty":-3.236529,"median":-1.423263,"eighty":-0.676786,"marketCap":1654628}],"updateTime":1746112666766}}}